Form 4: Arcutis Director Sells 10,000 Shares Under 10b5-1 Plan

Arcutis Biotherapeutics Director Howard G. Welgus sold 10,000 shares of common stock for a weighted average price of $30.2133 per share, executed under a pre-arranged 10b5-1 trading plan.

Summary

• Howard G. Welgus, a Director of Arcutis Biotherapeutics, Inc. (ARQT), reported a sale of common stock.
• The transaction involved the disposition of 10,000 shares of common stock.
• The shares were sold on December 1, 2025, at a weighted average price of $30.2133 per share.
• The total value of the shares sold is approximately $302,133.
• Following this transaction, Welgus beneficially owns 79,744 shares of Arcutis Biotherapeutics common stock directly.
• The sale was executed pursuant to a Rule 10b5-1 trading plan adopted on March 11, 2025, with a plan end date of May 29, 2026.
• The shares were sold in multiple transactions at prices ranging from $29.85 to $30.5650.

Sentiment

Score: 5

Explanation: Neutral. The transaction is a pre-planned insider sale under a 10b5-1 plan, which typically reduces concerns about opportunistic timing and is a routine event for executives managing personal finances.

Negatives

• Insider selling, even if planned, can sometimes be viewed with slight caution by investors, though a 10b5-1 plan mitigates concerns about opportunistic timing.

Future Outlook

This filing does not contain any forward-looking statements or guidance regarding the company's future outlook.

Industry Context

This insider transaction report is specific to an individual director's stock activity and does not provide information directly related to broader industry trends or competitive landscape.

Stakeholder Impact

• Shareholders might note the insider sale, but the pre-arranged 10b5-1 plan mitigates concerns about its implications for company performance or future prospects.

Key Dates

Keywords

Arcutis Biotherapeutics, ARQT, Howard G. Welgus, Insider Trading, Form 4, Stock Sale, 10b5-1 Plan, Director, Biotechnology